Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia.

Aasma Shaukat¹, Theodore R Levin², Peter S Liang¹, Jennifer M Weiss³, Caitlin Smare⁴, Emily Boller⁴, Meena Venkatachalam⁴, Erica K Barnell⁵

¹Division of Gastroenterology, NYU Grossman School of Medicine, New York, New York; Department of Medicine, VA New York Harbor Health Care System, New York, New York.

²Kaiser Permanente Division of Research, Pleasanton, California.

³Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

⁴Precision AQ, London, United Kingdom.

⁵Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri; Geneoscopy Inc, Saint Louis, Missouri. Electronic address: e.barnell@wustl.edu.

PubMed DOI

Abstract

BACKGROUND & AIMS: This study assessed the economic and health impact of colorectal cancer (CRC) screening programs for average-risk individuals aged 45 years and older. METHODS: A 10-year Markov model simulated disease progression, comparing multitarget stool RNA test (mt-sRNA, ColoSense), two mt-sDNA tests (Cologuard and Cologuard Plus), a blood-based test (cfDNA, Shield), and a fecal immunoche…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.